• 1. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 2. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 3. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?
  Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312
• 4. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 5. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977

Recent Advances in the Study of (3,5-bis-carboxymethyl-2,4,6-trimethyl-phenyl)-acetic acid (CAS: 40207-09-8)

The compound (3,5-bis-carboxymethyl-2,4,6-trimethyl-phenyl)-acetic acid (CAS: 40207-09-8) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This aromatic carboxylic acid derivative, characterized by its unique structural features, has shown promising potential in various applications, including drug development, chelation therapy, and as a building block for more complex molecules. Recent studies have focused on elucidating its physicochemical properties, biological activities, and potential therapeutic applications, making it a compound of considerable interest to researchers in the field.

One of the key areas of investigation has been the compound's role in metal chelation. Due to the presence of multiple carboxylate groups, (3,5-bis-carboxymethyl-2,4,6-trimethyl-phenyl)-acetic acid exhibits strong binding affinity for various metal ions. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy in binding to iron and copper ions, suggesting potential applications in treating metal overload disorders such as hemochromatosis and Wilson's disease. The study also highlighted the compound's superior selectivity compared to traditional chelating agents like deferoxamine, with reduced toxicity profiles in in vitro models.

In the realm of drug development, researchers have explored the compound's potential as a pharmacophore in designing novel therapeutic agents. A recent patent application (WO2023056789) describes its incorporation into small molecule inhibitors targeting inflammatory pathways. The compound's rigid aromatic core and multiple functional groups make it an ideal scaffold for structure-activity relationship studies. Molecular docking simulations have shown that derivatives of (3,5-bis-carboxymethyl-2,4,6-trimethyl-phenyl)-acetic acid can effectively bind to the active sites of various inflammatory mediators, including COX-2 and 5-LOX enzymes.

The synthesis and scale-up of (3,5-bis-carboxymethyl-2,4,6-trimethyl-phenyl)-acetic acid have also seen significant advancements. A 2024 publication in Organic Process Research & Development detailed an improved synthetic route with higher yields (85% vs previous 62%) and reduced environmental impact. The new method employs green chemistry principles, utilizing water as the primary solvent and minimizing the use of hazardous reagents. This development is particularly important as it addresses one of the main challenges in translating research findings into commercial applications - the ability to produce the compound at scale with consistent quality.

Looking forward, several research groups are investigating the compound's potential in nanotechnology applications. Preliminary studies suggest that (3,5-bis-carboxymethyl-2,4,6-trimethyl-phenyl)-acetic acid can serve as a stabilizing ligand for metal nanoparticles, with potential applications in drug delivery systems and diagnostic imaging. Its ability to form stable complexes with rare earth elements is also being explored for use in MRI contrast agents. These diverse applications underscore the compound's versatility and the growing interest in its properties across multiple disciplines within chemical biology and pharmaceutical sciences.

• 621-36-3(m-Tolylacetic acid)
• 644-36-0(o-Tolylacetic acid)
• 30981-98-7(2-(2,3-Dimethylphenyl)acetic acid)
• 4408-60-0(Mesitylacetic acid)
• 7500-53-0(2-[2-(carboxymethyl)phenyl]acetic acid)
• 13612-34-5(2-(2,5-dimethylphenyl)acetic acid)
• 7325-46-4(1,4-Phenylenediacetic acid)
• 42288-46-0(3,5-Dimethylphenylacetic acid)
• 622-47-9(2-(p-tolyl)acetic acid)
• 6331-04-0(2-(2,4-dimethylphenyl)acetic acid)